Do you or someone you care about have MS? MS PathwaysSM is the source for personalized support for BETASERON patients and those considering BETASERON therapy. Take advantage of the many helpful tools offered by MS PathwaysSM, including a year-round Personal Patient Journal with plenty of room for notes, healthcare instructions, and injection reminders.
Starting and staying on BETASERON successfully may be achieved with the guidance of your healthcare team, and the support of MS PathwaysSM.
As with all MS therapies, you may experience some side effects when starting BETASERON. Methods have been developed to help reduce or prevent side effects such as flu-like symptoms and injection-site reactions that are associated with any interferon treatment.
The thought of injecting yourself can be a little uncomfortable at first. But soon you will find that it may be a lot less painful and scary than you originally expected. Learn about Injection Techniques
Tylenol is a registered trademark of McNeil Consumer Healthcare, a Division of McNeil PPC, Inc. Motrin is a registered trademark of McNeil Consumer Healthcare, a Division of McNeil PPC, Inc. Aleve is a registered trademark of Bayer HealthCare LLC.
Reference:BETASERON® (Interferon beta-1b) is indicated for the treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations. Patients with multiple sclerosis in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis.
Important Safety Information
The most commonly reported adverse reactions are lymphopenia, injection-site reaction, asthenia, flu-like symptom complex, headache and pain. Gradual dose titration and use of analgesics during treatment initiation may help reduce flu-like symptoms. BETASERON should be used with caution in patients with depression. Injection-site necrosis has been reported in 4% of patients in controlled trials. Patients should be advised of the importance of rotating injection sites. Female patients should be warned about the potential risk to pregnancy. Cases of anaphylaxis have been reported rarely. See "Warnings," "Precautions," and "Adverse Reactions" sections of full Prescribing Information.